Emerging Concepts for the Treatment of Hematological Malignancies with Therapeutic Monoclonal Antibodies

Author(s): Aude-Helene Capietto, Samarh Keirallah, Emilie Gross, Nicolas Dauguet, Emilie Laprevotte, Christine Jean, Julie Gertner-Dardenne, Christine Bezombes, Anne Quillet-Mary, Mary Poupot, Loic Ysebaert, Guy Laurent, Jean-Jacques Fournie

Journal Name: Current Drug Targets

Volume 11 , Issue 7 , 2010

Become EABM
Become Reviewer


The development of therapeutic monoclonal antibodies (mAbs) has revolutionized the treatment of cancer along the last ten years. The best examples of their therapeutic efficacies have been obtained with rituximab for the treatment of CD20+ B-cell Non-Hodgkin Lymphoma (B-NHL), and several others antibodies with optimized bioactivities are now being developed for the treatment of various malignant hemopathies. We review here the main drugs developed in this field, and present some emerging concepts able to improve the bioactivities of the next generation of therapeutic mAbs.

Keywords: Cancer, lymphoma, therapy, antibodies, phosphoantigens

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2010
Page: [790 - 800]
Pages: 11
DOI: 10.2174/138945010791320845
Price: $65

Article Metrics

PDF: 9